Literature DB >> 23403985

Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells.

Masashi Shiiba1, Kengo Saito, Kazuaki Fushimi, Takashi Ishigami, Keiji Shinozuka, Dai Nakashima, Yukinao Kouzu, Hirofumi Koike, Atsushi Kasamatsu, Yosuke Sakamoto, Katsunori Ogawara, Katsuhiro Uzawa, Yuichi Takiguchi, Hideki Tanzawa.   

Abstract

The aim of the present study was to identify a target molecule that could predict the efficacy of radiotherapy in oral squamous cell carcinoma (OSCC). We used DNA microarray analysis to identify differences in gene expression after X-ray irradiation. We compared the gene expression profiles between X-ray (8 Gy)-irradiated Ca9-22 cells (an OSCC-derived cell line) and unirradiated Ca9-22 cells. A total of 167 genes with a 2-fold higher level of expression induced by X-ray irradiation were identified. Lipocalin-2 (LCN2) had the greatest increase in expression after X-ray irradiation, and it was categorized in a network that has cancer-related functions with the Ingenuity Pathway Analysis tool. Upregulated expression of LCN2 mRNA was validated by real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis. When the LCN2 gene was knocked down in OSCC cells (Ca9-22 and HSC-2) and lung cancer cells (A549) by using small interfering RNA, the radiosensitivity of these cells was enhanced. Our findings suggest that the overexpression of LCN2 is likely associated with radioresistance in oral cancer and lung cancer cells, and that LCN2 expression levels could be used to predict radioresistance. Thus, regulating the expression or function of LCN2 could enhance the radiation response, resulting in a favorable outcome of radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403985     DOI: 10.3892/ijo.2013.1815

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

1.  Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.

Authors:  Blanca D López-Ayllón; Javier de Castro-Carpeño; Carlos Rodriguez; Olga Pernía; Inmaculada Ibañez de Cáceres; Cristobal Belda-Iniesta; Rosario Perona; Leandro Sastre
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 2.  Regulation of cellular iron metabolism and its implications in lung cancer progression.

Authors:  Wei Xiong; Li Wang; Fenglei Yu
Journal:  Med Oncol       Date:  2014-05-27       Impact factor: 3.064

3.  Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer.

Authors:  Sarah Yoon; Eun-Ju Lee; Ji-Hye Choi; Taek Chung; Do Young Kim; Jong-Yeop Im; Myung-Ho Bae; Jung-Hee Kwon; Hyuk-Hoon Kim; Hyung Chul Kim; Young Nyun Park; Hee-Jung Wang; Hyun Goo Woo
Journal:  Oncogene       Date:  2018-05-03       Impact factor: 9.867

Review 4.  Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types.

Authors:  Sina Rahimi; Amaneh Mohammadi Roushandeh; Ebrahim Ahmadzadeh; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Mol Biol Rep       Date:  2020-01-22       Impact factor: 2.316

5.  WWP2 is overexpressed in human oral cancer, determining tumor size and poor prognosis in patients: downregulation of WWP2 inhibits the AKT signaling and tumor growth in mice.

Authors:  Chonji Fukumoto; Dai Nakashima; Atsushi Kasamatsu; Motoharu Unozawa; Tomomi Shida-Sakazume; Morihiro Higo; Katsunori Ogawara; Hidetaka Yokoe; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  Oncoscience       Date:  2014-11-28

Review 6.  Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities.

Authors:  Caiguo Zhang; Fan Zhang
Journal:  Protein Cell       Date:  2014-12-06       Impact factor: 14.870

7.  Safety and effectiveness of localized lung resection combined with neoadjuvant chemotherapy in the treatment of stage I-II non-small cell lung cancer.

Authors:  Bing Zhu; Jianru Yang; Pei Zhang; Lin Shen; Xiaolong Li; Jing Li
Journal:  Oncol Lett       Date:  2017-02-03       Impact factor: 2.967

8.  Gprc5a-knockout mouse lung epithelial cells predicts ceruloplasmin, lipocalin 2 and periostin as potential biomarkers at early stages of lung tumorigenesis.

Authors:  Beibei Sun; Wenzheng Guo; Song Hu; Feng Yao; Keke Yu; Jie Xing; Ronghua Wang; Hongyong Song; Yueling Liao; Tong Wang; Pengfei Jiang; Baohui Han; Jiong Deng
Journal:  Oncotarget       Date:  2017-02-21

Review 9.  Biological Functions and Therapeutic Potential of Lipocalin 2 in Cancer.

Authors:  Ginette S Santiago-Sánchez; Valentina Pita-Grisanti; Blanca Quiñones-Díaz; Kristyn Gumpper; Zobeida Cruz-Monserrate; Pablo E Vivas-Mejía
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

10.  Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma.

Authors:  Raj Kumar Mongre; Simrinder Singh Sodhi; Neelesh Sharma; Mrinmoy Ghosh; Jeong Hyun Kim; Nameun Kim; Yang Ho Park; Young Gyu Shin; Sung Jin Kim; Zhang Jiao Jiao; Do Luong Huynh; Dong Kee Jeong
Journal:  Int J Oncol       Date:  2015-11-13       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.